I've been dabbling in the markets for years and have never figured out why market capitalization seems so arbitrary. PLX seems to be a great company with a potentially profitable product in its pipeline, but does it really justify a $400 million market cap? How about a company like IBIO, with a market cap in the toilet and market action that looks a lot like somebody is intentionally driving its value down? IBIO has multiple potential products and incredible technology, so why doesn't the market value it in the same range as PLX? Maybe I should be keeping my thoughts to myself and just quietly pile up a position in IBIO before the market discovers it!
Being held up by institutions...this will have a billion dollar market cap soon once a deal with Brazil is done...and hopefully soon...Big support around $5. We'll see where it takes us from here. Good luck.
Sentiment: Strong Buy
Thanks. But what I'm looking for is an outside reference or statement of recognition that the PLX platform is derived from his work. Running down a slew of unreadable, unintelligible patents won't do it. That, typically, is a matter of interpretation -- usually best left to the courts. So where would I look to find a reference that puts Erwin and PLX in the same sentence. Better still, just quote it here and cite the source. Thanks again.
Good observations. I've been looking at stocks whose prices have dropped near year end, maybe due to tax loss selling. The losses of one investor set the stage for the profits of another.
With regard to PLX and IBIO, I see no reason for such a wide value gap. Assuming PLX is fairly valued, then IBIO is way under valued and ripe for accumulation.
plx will get approved, spike like a mofo, then the market will immediately short the company as it struggles with commercialization realities and the smart money will go hand-over-fist into ibio simultaneously. PLX=Gateway Drug and is a necessary step in the process of a paradigm shift to plant-based platforms/methods and I hope it is successful. It's an interesting predicament really, in that IBIO will benefit greatly from the approval and success of PLX, only PLX will ultimately lag as a result of ibio's successes.
good luck everyone